ImmuCell (ICCC) Lytham Partners 2025 Industrials & Basic Materials Investor Summit summary

Strategic milestones and product focus

• 2025 is expected to bring significant milestones for both the First Defense and Re-Tain product lines, with commercial and regulatory advancements anticipated.

• First Defense remains the core asset, offering USDA-approved, colostrum-derived antibody protection against major calf diseases.

• Re-Tain, an FDA-regulated mastitis treatment using bacteriocins, is nearing the end of a lengthy development and approval process.

• The company positions itself as a nimble, innovative alternative to traditional animal health firms, focusing on non-antibiotic solutions.

• Reducing antibiotic use in livestock is a key differentiator, with both products offering alternatives to conventional treatments.

Product differentiation and market positioning

• First Defense delivers immediate, uniform immunity to calves via colostrum-derived antibodies, targeting E. coli, coronavirus, and rotavirus.

• Tri-Shield, a newer SKU, adds rotavirus protection, making it unique in covering all three major pathogens.

• Competing products are primarily vaccines, which are less effective in newborn calves due to their underdeveloped immune systems.

• First Defense's direct antibody delivery bypasses the need for an immune response, providing consistent protection.

• The U.S. market for scour prevention is valued at $83 million, with the company holding a 15% share.

Manufacturing, capacity, and operational challenges

• Recent years saw significant production expansion, requiring partnerships with more farms and investments in facilities.

• The company overcame major contamination issues during capacity scaling, achieving nearly a year of clean, high-output operations by 2024.

• Current production capacity is around $30 million, with plans to reach $40 million deferred due to cash constraints.

• The sales team demonstrated resilience, maintaining customer relationships and rebounding strongly in 2024 despite supply volatility.